Canadian Health Authority invests in CellaVision's newest analyzer
(Thomson Reuters ONE) - CellaVision, which develops and sells digital morphology products forthe routine analysis of blood and other body fluids, has received itsfirst Canadian order for the recently launched product CellaVision®DM1200. The order is for three analyzers, to be installed at smalland mid-sized hospital sites throughout the health authority.Including the two CellaVision DM96 analyzers purchased earlier thisyear, the customer now has a total of five systems. The objective isto improve the quality of the manual differential results acrosshospitals of all sizes throughout the region."Maintaining close customer relations and earning their trust are twoof the most important factors in our ability to innovate and findsolutions to our customer's problems, says Yvonne Mårtensson, CEO ofCellaVision. "Our customer's decision to further invest in ourdigital morphology system confirms that we have succeeded in meetingthe Canadian hematology market's requirements for improving theanalytical flow, even for the smaller laboratory. It is strategicallyimportant for us to be entrusted to deliver a new product this soonafter its introduction to the market, showing their confidence indoing business with CellaVision."The CellaVision® DM1200 replaces manual microscopy of blood samplesand is aimed at hospital laboratories and independent commerciallaboratories. Besides extra efficiency in the laboratory, theCellaVision automated technology permits proficiency and connectivityas the results of the analysis can be viewed from anywhere in thehospital, such as the physician's office. The distribution betweendifferent types of blood cells and their appearance are importantcriteria in diagnosis of a number of conditions such as infectionsand blood diseases.The CellaVision products are sold in Canada by the subsidiaryCellaVision Canada Inc. Since obtaining its first Health Canadaapproval in 2007, the subsidiary has already sold over 30 instrumentsto Hospitals and Reference Laboratories in Ontario, British Columbia,Quebec, Saskatchewan, Nova Scotia and Newfoundland.For more information, please contact:Yvonne Mårtensson, CEO, CellaVision ABPhone: +46 708 33 77 82. E-mail: yvonne.martensson(at)cellavision.comAbout CellaVisionCellaVision AB develops, markets, and sells market leading imageanalysis based systems for routine analysis of blood and other bodyfluids. The company has a core competence in development of softwareand hardware for automatic image analysis of cells and cell changesfor applications in health and medical care. The company develops andmarkets systems for automatic differentials of white blood cells andred morphology, and software for education and quality assurance ofdifferentials. The company's associates have expertise in advancedimaging analysis, artificial intelligence, and automated microscopy.The company headquarters are in Lund, Sweden. The company also hassubsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan.For more information, visit www.cellavision.com.CellaVision's share is listed on First North Premier at the OMXStockholm Stock Exchange. The company's Certified Advisor is RemiumAB.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 11.12.2009 - 08:31 Uhr
Sprache: Deutsch
News-ID 9504
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 687 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Canadian Health Authority invests in CellaVision's newest analyzer"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
